Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain--biopharmaceutic and pharmacokinetic challenges.
Recent published evidences on ibuprofen and meloxicam confirm the need of faster oral drug absorption to overcome the pathophysiological conditions associated with dental pain (due to excessive vagal nerve suppression) in order to provide relief in acute pain management. While the communication provides relevant case studies to support the hypothesis in both dental pain and migraine attacks, it also provides biopharmaceutical and pharmacokinetic challenges of developing such a strategy for faster oral drug absorption. It is envisaged that the unmet need in this area, to overcome the pathophsiological barriers, should provide impetus for further research exploration in formulation strategies and biopharmaceutical/pharmacokinetic integration.
Srinivas
Nuggehally R
NR
Integrated Drug Development, Suramus Biopharm, J.P. Nagar, I Phase, Bangalore 560 078, India. srini.suramus@yahoo.com
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D001702:Biopharmaceutics; D002626:Chemistry, Pharmaceutical; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D007408:Intestinal Absorption; D000077239:Meloxicam; D013843:Thiazines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D013844:Thiazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D014098:Toothache / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam; D007052:Ibuprofen